Research SummaryI am an academic neuro-oncologist involved in clinical care, clinical research and teaching. I have extensive experience as well as formal training in clinical trial development, implementation, and analysis, including investigator-initiated, sponsored, and multi-institutional consortium and cooperative group studies testing new treatments and treatment combinations in gliomas.
I am a Co-Associate Director of the Clinical Core for the new UCSF (P01) Program Project Grant to integrate advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). I am a co-investigator in all of the current neuro-oncology therapeutic trials, as well as in several non-therapeutic studies in the areas of diagnosis, epidemiology, and quality of life. In addition, I am the principal investigator at UCSF for six active protocols.
I am study chair for a single-institution investigator-initiated study treating newly-diagnosed, subtotally resected low-grade gliomas with chemotherapy, everolimus alone or in combination with temozolomide; the treatment is selected based on molecular parameters of the patient’s tumor. This study incorporates both imaging and molecular objectives, in collaboration with colleagues from the BTRC. I am also the PI of a phase I dose-escalation study in collaboration with Memorial Sloan-Kettering, combining bevacizumab (an anti-VEGF antibody) with hypofractionated stereotactic radiation in recurrent malignant glioma. In addition to anti-tumor properties, it is thought that bevacizumab has some radio-protective properties, which may allow the stereotactic radiation dose to be escalated higher than would otherwise be tolerated. Another study is a multi-center, randomized phase II study from the ALLIANCE. It randomizes patients between three arms: an autologous heat-shock protein vaccine followed by bevacizumab at recurrence, an autologous heat-shock protein vaccine in combination with bevacizumab, or bevacizumab alone. An additional multi-center study tests a checkpoint inhibitor, MEDI4736, in combination with radiation in patients with newly-diagnosed GBMs that are MGMT unmethylated, or in combination with bevacizumab in patients with recurrent, bevacizumab-refractory GBMs.
In addition to these clinical trials, we have an ongoing longitudinal study assessing quality of life in patients with malignant gliomas undergoing initial therapy, for which I am coordinating analysis.
California Institute of Technology (Caltech), Pasadena, CA, B.S., 1995, Chemistry, With Honor
University of California, San Francisco, M.D., 2002, Medicine
University of California, Berkeley, M.P.H., 2001, Health Policy and Mgmt
St. Mary’s Medical Center, San Francisco, 06/03, Intern, Internal Medicine
University of California, San Francisco, 06/06, Resident, Neurology
Memorial Sloan-Kettering Cancer Center, 06/08, Fellow, Neuro-oncology
St. Mary’s Medical Center, San Francisco Intern Medicine
University of California, San Francisco Resident Neurology
University of California, San Francisco Chief Resident Neurology
Memorial Sloan-Kettering Cancer Center Fellow Neuro-Oncology
Memorial Sloan-Kettering Cancer Center Chief Fellow Neuro-Oncology
University of California, San Francisco Assistant Clinical Professor of Neurology and Neurological Surgery (Division of Neuro-Oncology)
8/10 – present
University of California, San Francisco Assistant Professor of Clinical Neurology and Neurological Surgery (Division of Neuro-Oncology)